Bayer AG Standardizes on Veeva Vault Clinical Applications Globally
23.7.2020 14:03:00 EEST | Business Wire | Press release
Veeva Systems (NYSE:VEEV) today announced that Bayer AG (ETR:BAYN) has selected Veeva Vault Study Startup and Veeva Vault eTMF globally to accelerate site activation and improve visibility across trials.
“Veeva cloud applications will enable us to streamline trial execution,” said Joerg Moeller, Head of Pharma R&D at Bayer AG. “We appreciate Veeva’s modern technology and customer-centric approach to partnership.”
Veeva will enable Bayer AG to manage clinical content and data on a single cloud platform to unify their operations. Vault Study Startup streamlines end-to-end study start-up processes from site identification to site greenlight. Vault eTMF enables active TMF management for real-time visibility and control, helping life sciences companies meet compliance regulations to stay inspection ready.
Bringing both these applications together will enable Bayer AG’s clinical teams to eliminate manual processes, share the same trial documents, and automatically file content from Vault Study Startup in Vault eTMF.
“Life sciences companies are adopting Veeva Vault Clinical applications to speed study execution as they manage a growing number of clinical trials,” said Rik Van Mol, vice president of strategy for Veeva Development Cloud. “Now Bayer AG will be able to have a complete view of trial documents from study activation to study close, while maintaining a constant state of inspection readiness.”
Vault Study Startup and Vault eTMF are part of the Veeva Vault Clinical Suite, the industry’s first cloud platform that includes CDMS, Study Startup, eTMF, CTMS, and Payments to unify clinical data management and clinical operations. Veeva’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes.
Learn more about Veeva Vault Clinical Suite at the upcoming Veeva R&D and Quality Summit, October 13-14, 2020. The virtual event is only open to life sciences industry professionals. Register and stay up-to-date on program details at veeva.com/R&DSummit. Also, watch the on-demand presentations from Veeva R&D and Quality Summit, Europe at veeva.com/EUSummit.
Additional Information
For more on Veeva Vault Clinical Suite, visit: veeva.com/Clinical
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005073/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 12:21:00 EEST | Press release
Fourthline, Europe's identity verification and compliance leader, has signed an agreement to merge with Veridas, a recognised international digital identity provider, to deliver the most complete and advanced trust platform across Europe and the Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629494028/en/ Paul Stoddart, CEO of Fourthline The combination unites Fourthline's institutional-grade KYC/AML compliance orchestration across Northern and Central Europe with Veridas's proprietary identity and anti-fraud stack and market position in Southern Europe, the US, and Latin America. Operating under a single, integrated AI architecture, the combined entity will secure the entire customer lifecycle for global Tier-1 banks, fintechs, telecommunications providers, and digital disruptors across both continents. Fourthline and Veridas come together from a position of strength, both profitable, EBITDA-positive, and at th
Tax Systems Rebrands as Alphatax16.7.2026 11:00:00 EEST | Press release
Tax Systems, a global tax and accounting software provider, today announced it is rebranding as Alphatax, aligning the company with its flagship corporation tax compliance solution and marking the next stage in its evolution as an AI-first technology business. The rebrand reflects the company's ambition to redefine how tax professionals work through connected, AI-powered technology. As Alphatax, the business is bringing together compliance, data, governance and intelligence into a single platform, creating the foundations for the world’s first tax operating system: a connected environment where tax data, decisions, approvals, filings and evidence can come together. The new identity builds on the strong reputation of Alphatax, a market-leading corporation tax software trusted by tax professionals across the world. Bringing the company’s expanding portfolio together under one master brand will provide customers with a more connected experience across corporate tax, Pillar Two, transfer p
SWISSto12 Closes US$70 Million Series C to Meet Growing Multi-Orbit Demand16.7.2026 10:00:00 EEST | Press release
SWISSto12, a leading enabler of the new space economy, today announced the close of its $70 million (€61 million) Series C. This news follows the award of $84.8 million (€73 million) from European Space Agency (ESA) Member States to the HummingSat ARTES partnership project, through which ESA supports SWISSto12 in the development and in-orbit validation of HummingSat. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716342732/en/ SWISSto12 will scale its manufacturing and integration capacity to meet accelerating demand from commercial and sovereign government customers. The Series C fundraise follows a period of sustained commercial growth for the company, with revenues of $140 million (€121 million) for 2025 and total contract values now exceeding $500 million (€432 million), driving positive EBITDA in 2026. To date, SWISSto12 has secured seven contracts for its HummingSat geostationary (GEO) small satellite with leading g
AMINA Becomes the First Regulated Bank to Integrate Leading Crypto Payments Network, Mesh16.7.2026 09:30:00 EEST | Press release
AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today becomes the first regulated bank to integrate Mesh, the leading crypto payments network. The integration embeds Mesh’s verified deposit technology directly into AMINA’s online banking platform. This allows clients to verify wallet ownership, and deposit stablecoins and digital assets in a single, streamlined flow across more than 300 wallet providers. No more copying wallet addresses by hand, switching between external tools, or completing the multi-step verification the process historically required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715917516/en/ AMINA is the first regulated bank on Mesh. Myles Harrison, Chief Product Officer at AMINA, said: “Despite the incredible progress the industry has made in institutional adoption, crypto remains difficult to move safely and efficiently betwe
Garvan Institute of Medical Research Joins Parse Biosciences’ Certified Service Provider Network15.7.2026 23:00:00 EEST | Press release
Parse Biosciences, a QIAGEN company, and the leader in scalable and accessible single cell sequencing, today announced that the Genomics Platform Core Facility within the Garvan Institute of Medical Research has joined its Certified Service Provider (CSP) Program. The partnership broadens access to high-quality, scalable single cell sequencing across Australia, the wider Asia-Pacific region, and beyond. Garvan is one of Australia's preeminent medical research institutions, with the Genomics Platform having deep experience in cell sorting, capture, and sequencing. As a Certified Service Provider, Garvan will offer Parse's Evercode WT kits to researchers across the region. "We see a growing number of requests for Parse projects and find the technology easy to implement and run, generating great data," said Chris O'Keeffe, Cellular Genomics Lead at the Garvan Institute. "Garvan is one of the most respected biomedical research institutions in the world, and we're honored to welcome them to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom